Indication
Parkinson's Disease Dementia
3 clinical trials
3 products
Product
CST-103Clinical trial
A Phase II, Randomized, Placebo-Controlled, Double-Blind, Crossover, Study of the Pharmacodynamic Effects of CST-103 Co-administered With CST-107 on the Central Nervous System in Subjects With Neurodegenerative DisordersStatus: Active (not recruiting), Estimated PCD: 2022-07-04
Clinical trial
A Randomized, Double Blinded, Placebo-controlled Phase II Study to Assess the Efficacy and Safety of Ceftriaxone in Patients With Mild to Moderate Parkinson's Disease DementiaStatus: Recruiting, Estimated PCD: 2024-12-31
Product
CeftriaxoneClinical trial
Ambroxol as a Novel Disease Modifying Treatment for Parkinson's Disease DementiaStatus: Active (not recruiting), Estimated PCD: 2025-12-01
Product
Ambroxol